Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (RXST) delivers groundbreaking light adjustable lens technology that transforms post-cataract surgery outcomes. This dedicated news hub provides investors and medical professionals with essential updates on the company's clinical advancements and strategic developments.
Access official press releases covering product innovations, financial performance, and regulatory milestones. Our curated collection includes updates on the Light Adjustable Lens system's clinical adoption, partnership announcements with leading ophthalmology centers, and research breakthroughs in customized vision correction.
Key areas of coverage include quarterly earnings reports, FDA clearances for new device iterations, and peer-reviewed study results validating LAL technology outcomes. Stay informed about manufacturing expansions and international market entries that demonstrate RXST's growth trajectory in the premium intraocular lens sector.
Bookmark this page for real-time updates on how RxSight continues to redefine cataract care through its unique post-operative adjustment capabilities. Monitor critical developments that position the company at the forefront of personalized ophthalmic solutions.
RxSight (Nasdaq: RXST) reported third quarter 2025 results: Q3 revenue $30.3M (down 14% YoY) driven by 26,045 LAL lenses sold (+6% procedure volume) and 25 LDD devices sold (-69%). Gross margin was 80% (+844 bps YoY). The company narrowed full‑year 2025 revenue guidance to $125.0M–$130.0M, raised full‑year gross margin guidance to 76%–77%, and kept operating expense guidance at $145M–$155M (including stock‑based comp of $30M–$32M). Cash and short‑term investments totaled $227.5M as of September 30, 2025.
RxSight (Nasdaq: RXST) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025.
Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. To join by phone dial (800) 715-9871 or (646) 307-1963 and enter conference code 6619966.
The call will be broadcast in listen-only mode and archived on the company investor relations site at https://investors.rxsight.com/.
RxSight (Nasdaq: RXST) will host multiple Live Learning Sessions at AAO 2025 in Orlando, Oct 18–20, at Booth #2931. Sessions feature surgeons sharing real-world experience with the Light Adjustable Lens, focusing on clinical advantages and economic implications of adjustability.
Scheduled talks run Oct 18 (10:00 AM–3:00 PM) and Oct 19 (10:00 AM–1:00 PM) and cover topics such as ROI, career impact, premium lens adoption, patient-centered outcomes, and practical counseling for Light Adjustable Lens patients.
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has announced its participation in the upcoming Morgan Stanley Healthcare Conference in New York City.
The company's management team will deliver their presentation on September 8, 2025, at 10:45 AM ET. Investors can access both the live presentation and archived webcast through the company's investor relations website at investors.rxsight.com.
Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.
Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Wells Fargo Healthcare Conference in Boston. The company's management will deliver their presentation on September 4, 2025, at 10:15 AM ET. Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.rxsight.com.
RxSight (NASDAQ:RXST), an ophthalmic medical device company, reported mixed Q2 2025 financial results. Revenue decreased 4% year-over-year to $33.6 million, despite a 13% increase in Light Adjustable Lens (LAL) procedure volume to 27,380 units. The company's Light Delivery Device (LDD) installed base grew 34% to 1,084 units, though LDD sales declined 49% year-over-year.
The company reported a net loss of $(0.29) per share, compared to $(0.16) in Q2 2024. Gross margin improved to 74.9% from 69.5%. Notable developments include FDA approval for expanded LAL dioptric power range, launches in South Korea and Singapore, and a commercial organization realignment. RxSight maintained its full-year 2025 guidance of $120-130 million in revenue.
RxSight (Nasdaq: RXST), a medical device company specializing in customized vision solutions for cataract surgery patients, has appointed Raymond W. Cohen to its Board of Directors. Cohen, a seasoned medical technology executive with over 40 years of experience, notably led Axonics Inc. to generate over $1 billion in revenue within four years before its $3.7 billion acquisition by Boston Scientific in 2024.
As chairman of SoniVie Ltd., Cohen recently orchestrated its $600 million sale to Boston Scientific in March 2025. He currently serves on multiple healthcare company boards and brings extensive experience in scaling medical technology companies. Cohen expressed confidence in helping RxSight strengthen its position in the premium intraocular lens market and accelerate revenue and profit growth.
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers (800) 715-9871 or (646) 307-1963 with conference code 633359, or listen to the webcast through the company's investor relations website.
RxSight (NASDAQ: RXST), an ophthalmic medical device company, reported disappointing preliminary Q2 2025 results and significantly lowered its full-year guidance. Revenue is expected to be $33.6 million, down 4% year-over-year and 11% sequentially.
The company sold 27,380 Light Adjustable Lenses (up 13% YoY but down 1% QoQ) and 40 Light Delivery Devices (down 49% YoY and 45% QoQ). The installed base grew 34% YoY to 1,084 LDDs.
RxSight revised its 2025 guidance downward, now expecting revenue of $120-130 million (previously $160-175 million), while increasing gross margin guidance to 72-74% and reducing operating expense projections to $145-155 million.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
